Spyre Therapeutics, Inc. (SYRE) Stock Forecast
SYRE analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 4.83 / 5 from 18 analysts
- Price target
- $119.93 average of analyst targets
- Upside to target
- +50.1% from the latest close
- Next earnings
- November 3, 2026 EPS estimate $-0.79
- 52-week range
- $22.18 – $108.92
SYRE analyst ratings
18 analystsNumber of analysts at each rating.
SYRE price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
SYRE earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.82 | −$1.53 | −$0.66 | −$0.15 | −448.2% | 14 |
| Current fiscal year (2026) | −$2.85 | −$4.81 | −$2.37 | −$1.98 | −43.8% | 14 |
| Next fiscal year (2027) | −$3.52 | −$4.51 | −$2.59 | −$2.85 | −23.7% | 14 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
SYRE revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | 0.0% | 12 |
| Current fiscal year (2026) | $0 | $0 | $0 | 0.0% | 12 |
| Next fiscal year (2027) | $0 | $0 | $0 | 0.0% | 12 |
SYRE EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
SYRE EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.73 | −$0.81 | −$0.83 | −$0.83 | −$0.82 | +13.4% | 2 up · 8 down |
| Current fiscal year (2026) | −$2.95 | −$2.83 | −$2.88 | −$2.87 | −$2.85 | −3.4% | 9 up · 3 down |
| Next fiscal year (2027) | −$3.13 | −$3.44 | −$3.52 | −$3.52 | −$3.52 | +12.6% | 3 up · 8 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
SYRE earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; SYRE beat in 7 of 12.
What analysts expect from SYRE
18 analysts cover Spyre Therapeutics; their consensus rating is strong buy (4.83 on a 1–5 scale, where 5 is a strong buy). The average price target is $119.93, 50.1% above the latest close of $79.90. Analysts expect earnings of −$2.85 per share for 2026, −43.8% from a year earlier. For 2027 the average estimate is −$3.52 per share. Spyre Therapeutics beat the EPS estimate in 7 of the last 12 quarters.
Related: SYRE income statement, SYRE key metrics, SYRE chart. See the SYRE stock overview for the latest quote and news.
SYRE forecast FAQ
What is Spyre Therapeutics's price target?
The average analyst price target for Spyre Therapeutics is $119.93, 50.1% above the latest close of $79.90.
Is Spyre Therapeutics a buy, hold or sell?
Of 18 analysts covering Spyre Therapeutics, 16 rate it a strong buy, 1 a buy, 1 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Spyre Therapeutics's EPS forecast?
Analysts forecast −$2.85 per share for 2026 (range −$4.81 to −$2.37); for 2027 the estimate is −$3.52.
When does Spyre Therapeutics report earnings?
Spyre Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 3, 2026 after the market closes; the EPS estimate is $-0.79.
Does Spyre Therapeutics usually beat earnings estimates?
Spyre Therapeutics reported EPS at or above the analyst estimate in 7 of the last 12 quarters.